IP Library › Patent Application 13240465
Patent Application
App. No. 13/240,465

USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS IN COMBINATION WITH MONOCLONAL ANTIBODIES FOR TREATING IMMUNE DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/240,465
Abstract

The present invention relates to methods of treating an autoimmune disorder, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, monoclonal antibodies that selectively bind B-cell specific antigens.

Claims (2)

1 . A method for eliminating or substantially reducing an autoimmune disorder in a subject comprising administering a lymphocytotoxic but hematopoeitic stem cell sparing high-dose pulsed amount of an oxazaphosphorine drug to the subject, such that the subject's immune system reconstitutes without stem cell transplantation, and administering an effective amount of a monoclonal antibody that selectively binds a B-cell specific antigen, thereby to eliminate or substantially reduce the autoimmune disorder.

2 - 32 . (canceled)

Assignments (4)
CONFIRMATORY LICENSE Recorded Sep 13, 2018
From: THE JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 046868/0113 →
CERTIFICATE OF TITLE Recorded Oct 21, 2014
From: ACCENTIA BIOPHARMACEUTICALS, INC.
To: PABETI, INC.
Reel/Frame 034029/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2012
From: O'DONNELL, FRANCIS E., JR.; BONITZ, SUSAN; SANTOS, CARLOS
To: ACCENTIA BIOPHARMACEUTICALS, INC.
Reel/Frame 027664/0867 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2012
From: BRODSKY, ROBERT A.; JONES, RICHARD J.; KAPLIN, ADAM
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 027665/0777 →